STAAR Surgical Issues Preliminary First Quarter Net Sales for 2026
STAAR Surgical Company announced preliminary first-quarter net sales for 2026, expecting over $90 million, a significant increase from $42.6 million in Q1 2025. This growth was mainly driven by sales in China and continued double-digit growth in the Americas, leading to anticipated improved adjusted EBITDA. However, the company noted negative impacts in some EMEA and APAC regions due to geopolitical and macroeconomic challenges, and it is not providing forward revenue or earnings guidance.
STAAR Surgical Expects Q1 2026 Sales to More Than Double
STAAR Surgical announced preliminary Q1 2026 net sales are expected to exceed $90 million, more than doubling Q1 2025 sales and driven by strong demand in China and the Americas. Despite geopolitical and macroeconomic headwinds in parts of EMEA and APAC, the company anticipates significant adjusted EBITDA improvement due to an enhanced cost structure and normalized distributor inventories in China. However, TipRanks’ AI Analyst, Spark, rates STAA as Neutral due to deteriorating profitability and weak technicals, even with improved quarterly execution.
STAAR Surgical announces preliminary net sales for first quarter 2026
STAAR Surgical (NASDAQ: STAA) has announced its preliminary net sales for the first quarter of 2026. The company is a leading developer, manufacturer, and marketer of implantable lenses for the eye. This announcement provides an early look into their financial performance for the quarter.
Staar Surgical Up 21% on Preliminary Q1 Sales
Staar Surgical Co. saw its shares jump 21% in after-hours trading following preliminary Q1 net sales exceeding $90 million, significantly higher than analyst expectations of $67.6 million. This growth was largely driven by demand in China and double-digit growth in the Americas, despite negative impacts from geopolitical and macroeconomic headwinds in other regions. The company will release full Q1 results in early May.
STAAR Surgical stock surges 18% on strong Q1 sales beat
STAAR Surgical Company (NASDAQ:STAA) saw its stock surge 18% after hours due to preliminary Q1 net sales significantly exceeding Wall Street expectations. The company anticipates over $90 million in net sales, more than double the previous year's Q1, primarily driven by strong performance in China and the Americas. This strong sales growth, coupled with an improved cost structure, is expected to lead to a meaningful improvement in adjusted EBITDA, although geopolitical challenges in some regions negatively impacted sales.
Staar Surgical (STAA) Surges 18% Following Positive Q1 Pre-Annou
Staar Surgical (STAA) saw its stock price surge 18% after releasing preliminary first-quarter results that exceeded market expectations. The company, a manufacturer of implantable lenses, primarily generates revenue from its Implantable Collamer Lenses (ICL) and has a significant global market presence. Despite this recent boost and strong institutional ownership, the company faces challenges including negative earnings and margins, and a low Piotroski F-Score indicating potential operational inefficiencies.
China drives STAAR Surgical sales above $90M in early 2026
STAAR Surgical announced preliminary net sales exceeding $90 million for the first quarter of 2026, driven primarily by strong growth in China and continued double-digit growth in the Americas. The company expects a significant improvement in adjusted EBITDA due to higher net sales and an improved cost structure, fulfilling two key objectives for the year. This financial update was released ahead of its full earnings announcement due to upcoming interactions with the investment and ophthalmology communities.
Q1 2026 sales at STAAR Surgical (NASDAQ: STAA) more than double year over year
STAAR Surgical announced preliminary Q1 2026 net sales are expected to exceed $90 million, more than double the $42.6 million from Q1 2025, driven largely by strong growth in China and the Americas. The company anticipates a meaningful improvement in adjusted EBITDA due to an improved cost structure, despite facing challenges in the Middle East, EMEA, and APAC regions. STAAR plans to release full Q1 results and its 10-Q filing in early May 2026.
Rising Profit Forecasts Indicate Potential Growth for Staar Surgical (STAA) Shares
Staar Surgical (STAA) is seeing significant investor interest driven by favorable earnings projections and upward analyst revisions. The company holds a Zacks Rank #2 (Buy), with projected earning increases of 123.1% for the current quarter and 837.5% for the full year. This strong outlook and positive analyst sentiment suggest potential continued growth for STAA shares.
STAA Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial overview of STAAR Surgical Co (STAA), detailing its revenue breakdown, profitability margins, and a comparison with competitors. STAA primarily generates revenue from ICLs (97.4% of sales), maintaining a strong gross margin of 75.68% despite negative operating and net margins. The company, with a market capitalization of $1.00B, is benchmarked against BLFS and CDNA, highlighting its competitive gross margin.
Canaccord reiterates Hold on STAAR Surgical stock, $22 target
Canaccord Genuity has reiterated a Hold rating on STAAR Surgical (NASDAQ:STAA) with a $22.00 price target after the company reported a significant fourth-quarter revenue miss and a 32% decline in revenue over the last twelve months. Despite a difficult 2025, new interim co-CEOs are optimistic about improvement in 2026, driven by a recovering Chinese market and cost right-sizing, while the company maintains a strong balance sheet. The firm notes the EVO ICL is a highly underpenetrated technology with a strong gross margin, but expects near-term stock volatility.
Staar Surgical Co (STAA) Shares Up 3.28% on Apr 2
Shares of Staar Surgical Co (STAA) rose by 3.28% on April 2nd, trading at $19.98. Analysts have a mixed outlook, with an average target price of $19.72, suggesting a slight downside, while GuruFocus estimates a fair value of $34.37, indicating a significant upside.
STAAR Surgical Company (NASDAQ:STAA) Receives Average Rating of "Reduce" from Analysts
STAAR Surgical Company (NASDAQ:STAA) has received an average "Reduce" rating from eleven analysts, with an average 12-month price target of $19.21. This follows the company's recent earnings report where EPS of ($0.37) and revenue of $57.8 million both missed consensus estimates. Despite analyst skepticism, insider Broadwood Partners recently increased its stake in the company, purchasing over 300,000 shares.
STAAR Surgical (STAA) price target decreased by 13.10% to 20.12
The article reports that the price target for STAAR Surgical (STAA) has been decreased by 13.10% to $20.12. This indicates a revised outlook from analysts regarding the company's future stock valuation.
STAAR Surgical (STAA) price target decreased by 13.10% to 20.12
This article reports that the price target for STAAR Surgical (STAA) has been decreasedОбратите внимание, что, поскольку мне не был предоставлен исходный текст статьи, я не могу извлечь дополнительную информацию, такую как авторы или баннерное изображение. to $20.12, representing a 13.10% reduction. The content provided is minimal and does not offer further details regarding this financial adjustment.
Vanguard realigns reporting; holds 0 shares of STAAR Surgical (STAA)
The Vanguard Group has filed an amended Schedule 13G/A for STAAR Surgical Co, reporting 0 shares beneficially owned and 0% of common stock. This change follows an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their beneficial ownership separately in reliance on SEC guidelines. The filing, signed by Ashley Grim, Head of Global Fund Administration, indicates no positive or negative impact on the company.
Stocks making big moves this week: Shopify, Winnebago, Coinbase, STAAR Surgical, and Viavi Solutions
This article highlights several stocks that experienced significant movement this week, detailing the reasons behind their fluctuations. Shopify rose due to positive market sentiment, while Winnebago fell after mixed quarterly results and a weak outlook. Coinbase dropped following news of proposed stablecoin legislation, and Viavi Solutions climbed after a positive mention from Jim Cramer.
Defender Capital LLC. Takes $15.43 Million Position in STAAR Surgical Company $STAA
Defender Capital LLC acquired a new stake of 668,222 shares in STAAR Surgical Company (NASDAQ:STAA) worth approximately $15.43 million during the fourth quarter, making it their 8th largest position. This comes despite STAAR Surgical missing quarterly earnings expectations and carrying a "Reduce" consensus analyst rating. Insider buying has also been noted, with Broadwood Partners purchasing 316,017 shares and a total of 1,104,351 shares acquired by insiders over the past 90 days.
Tudor Investment Corp ET AL Purchases New Position in STAAR Surgical Company $STAA
Tudor Investment Corp ET AL has acquired a new stake in STAAR Surgical Company ($STAA), purchasing 153,052 shares valued at approximately $4.11 million. This makes Tudor Investment Corp ET AL the owner of roughly 0.31% of the medical instruments supplier. STAAR Surgical reported a weak quarter, missing EPS and revenue expectations, and currently holds a "Reduce" consensus analyst rating with an average price target of $19.21.
Why STAAR Surgical (STAA) stock is trading up today
The article states that STAAR Surgical (STAA) stock is trading up today. However, no further details or reasons for this increase are provided. The content is extremely brief, consisting of only the headline.
Why STAAR Surgical (STAA) Stock Is Trading Up Today
STAAR Surgical (STAA) stock rose 3.7% after Cencora announced the acquisition of EyeSouth Partners' retina business for $1.1 billion. While STAAR Surgical was not directly involved, the deal strengthened investor confidence in the broader ophthalmology sector. Despite the positive news, the company's shares remain volatile, having experienced a significant drop earlier in the year after a proposed acquisition by Alcon fell through.
STAAR Surgical Stock Rises After Adjournment Of Stockholders’ Meeting To Discuss Proposed Merger With Alcon
STAAR Surgical Company's stock increased following an announcement that its special meeting of stockholders has been adjourned to allow for more time to garner votes for its proposed merger with Alcon Inc. The adjourned meeting is now scheduled for April 5, 2026. The companies are working to obtain stockholder approval for the merger agreement.
STAAR Surgical Co stock faces acquisition scrutiny as Alcon deal advances amid analyst caution
STAAR Surgical Co faces scrutiny as its proposed acquisition by Alcon advances, with a prominent proxy advisor recommending shareholders reject the $15 per share all-cash deal due to undervaluation. The acquisition aims to bolster Alcon's portfolio in phakic intraocular lenses, leveraging STAAR's strong position with its EVO Visian ICL products. Analysts maintain a cautious stance on STAAR stock, with an average 12-month price target around $20-21 USD, implying potential downside if the acquisition falls through.
Polar Asset Management Partners Inc. Makes New $3.36 Million Investment in STAAR Surgical Company $STAA
Polar Asset Management Partners Inc. has made a new $3.36 million investment in STAAR Surgical Company, acquiring 125,000 shares. This comes despite STAAR Surgical missing its latest quarterly earnings and revenue estimates, reporting negative EPS and margins. Institutional ownership in STAAR Surgical stands at 96.7%, and analysts currently hold a consensus "Reduce" rating with an average target price of $19.21.
FDA expands approval for Staar Surgical's popular implantable lens
Staar Surgical has received expanded FDA approval for its EVO/EVO+ Visian ICL (implantable collamer lens) to include adults with hyperopia, or farsightedness. This approval allows the lens to treat a wider range of refractive errors, potentially increasing its market reach and benefitting more patients seeking vision correction.
STAAR Surgical (NASDAQ:STAA) Trading 4.5% Higher - What's Next?
STAAR Surgical (NASDAQ:STAA) saw its shares rise 4.5% despite a significant earnings and revenue miss, alongside thin trading volume. Insiders, notably Broadwood Partners, made substantial purchases, while analysts generally hold a "Reduce" rating with an average target price of $19.21. The company reported negative EPS and net margin, though revenue increased 18% year-over-year.
[Form 4] STAAR SURGICAL CO Insider Trading Activity
STAAR Surgical's interim co-CEO and president & COO, Warren Foust, reported insider trading activity involving equity compensation. He received a grant of 45,117 Restricted Stock Units (RSUs) on March 13, 2026, vesting in three equal annual installments beginning in 2027. Additionally, previously granted RSUs vested on March 12 and 14, 2026, converting into 37,500 shares of common stock, bringing his direct holdings to 63,588 common stock shares and 45,117 RSUs.
STAAR Surgical (STAA) awards 39,809 RSUs to Interim Co-CEO Andrews
STAAR Surgical (STAA) granted its Interim Co-CEO and CFO, Deborah J. Andrews, 39,809 restricted stock units (RSUs) on March 13, 2026, as an annual equity award. Each RSU represents one share of common stock and will vest in three equal installments through March 13, 2029. This transaction was formally reported in a Form 4 SEC filing.
Slotnik Capital LLC Takes Position in STAAR Surgical Company $STAA
Slotnik Capital LLC has acquired a significant new position in STAAR Surgical Company (NASDAQ:STAA), purchasing 635,000 shares valued at approximately $17.06 million, representing 5.3% of Slotnik’s holdings and a 1.28% stake in STAAR. This investment occurs despite STAAR Surgical missing quarterly earnings and revenue estimates, alongside an average analyst rating of "Reduce" and a target price of $18.94. Insider buying activity has also been noted, with Broadwood Partners and other insiders acquiring additional shares.
Broadwood boosts STAAR Surgical (STAA) stake with 670K-share open-market buys
Broadwood Partners, L.P., a significant owner and director affiliate of STAAR Surgical (STAA), purchased 670,213 shares of common stock in open-market transactions between March 11 and March 13, 2026. These buys increased Broadwood Partners' direct ownership to 16,123,842 shares. The transactions occurred at weighted average prices ranging from $17.18 to $18.84 per share, and Neal C. Bradsher, President of Broadwood Capital, also directly owns 25,900 shares.
STAAR Surgical jumps after Alcon raises offer to $30.75/share in cash (update)
STAAR Surgical shares rose significantly after Alcon reportedly increased its acquisition offer to $30.75 per share in cash. This updated bid comes after previous reports of Alcon's earlier, lower offers being rejected and indicates continued interest in acquiring STAAR Surgical.
Broadwood group (NASDAQ: STAA) reports 32.6% STAAR Surgical stake
Broadwood Partners, Broadwood Capital, and related individuals have updated their ownership in STAAR Surgical Company, collectively reporting beneficial ownership of 32.6% of outstanding shares. This amendment (SCHEDULE 13D/A) details the beneficial ownership of key individuals like Neal C. Bradsher and notes that Richard T. LeBuhn will cease to be a reporting person. The group stated they would continue to review their investment and may buy or sell shares, engaging with management and other shareholders to create value, but has no specific current plans for major corporate actions.
Quantbot Technologies LP Decreases Stock Holdings in STAAR Surgical Company $STAA
Quantbot Technologies LP significantly reduced its stake in STAAR Surgical Company by 92.3% in the third quarter, selling over 103,000 shares and retaining 8,632 valued at $232,000. This move follows STAAR Surgical missing its latest quarterly earnings estimates, reporting a loss of ($0.37) EPS against an expected $0.14, and lower-than-anticipated revenue. Despite institutional selling, there has been notable insider buying, with Broadwood Partners and company insiders acquiring a substantial number of shares recently.
Director at STAAR Surgical (STAA) receives 7,524 long-dated options
STAAR Surgical director and 10% owner Neal C. Bradsher was granted 7,524 stock options with an exercise price of $18.46 per share, expiring on March 5, 2036. These options will vest on the earlier of June 18, 2026, or the company's 2026 annual shareholder meeting, contingent on his continuous service. This grant serves as director compensation under the company's Amended and Restated Omnibus Equity Incentive Plan.
Magnetar Financial LLC Invests $32.36 Million in STAAR Surgical Company $STAA
Magnetar Financial LLC has acquired a new stake of 1,204,371 shares, valued at approximately $32.36 million, in STAAR Surgical Company (NASDAQ:STAA). This investment represents about 2.42% of STAAR Surgical's total shares. Despite significant institutional ownership and recent insider buying, STAAR Surgical recently missed its Q3 earnings estimates, reporting an EPS of $(0.37) against an expected $0.14, and analysts currently have a "Reduce" rating with a target price of $18.94.
Gabelli Funds LLC Buys Shares of 216,185 STAAR Surgical Company $STAA
Gabelli Funds LLC recently acquired 216,185 shares of STAAR Surgical Company (STAA) valued at $5.81 million, establishing a new position in the medical instruments supplier. This purchase contributes to a total institutional ownership of 96.7% for STAAR Surgical, despite the company having recently missed earnings expectations with an EPS of -$0.37 and revenue of $57.8 million. Analysts currently have an average "Reduce" rating for STAA with a target price of $18.94, while insiders have also made significant purchases totaling $9.42 million over the last three months.
STAAR Surgical Co. Experiences Evaluation Revision Amidst Fluctuating Market Conditions
STAAR Surgical Co., a small-cap pharmaceuticals and biotechnology company, has undergone an evaluation revision due to fluctuating market conditions. The company's stock price has declined, leading to mixed technical indicators with bearish weekly signals and a mildly bullish monthly trend. Despite strong short-term performance relative to the S&P 500, STAAR Surgical has significantly lagged the index over the long term.
GABELLI & Co INVESTMENT ADVISERS INC. Makes New $4.81 Million Investment in STAAR Surgical Company $STAA
GABELLI & Co INVESTMENT ADVISERS INC. has invested $4.81 million in STAAR Surgical Company (NASDAQ:STAA), acquiring 179,000 shares in the third quarter. This new position makes GABELLI & Co INVESTMENT ADVISERS INC. a 0.36% owner of the medical instruments supplier. Other institutional investors also increased their stakes in STAAR Surgical, and insiders recently purchased over 434,000 shares, signaling confidence despite mixed analyst ratings and recent negative earnings.
STAAR Surgical Company (NASDAQ:STAA) Given Consensus Recommendation of "Reduce" by Brokerages
STAAR Surgical Company (NASDAQ:STAA) has received a consensus "Reduce" recommendation from twelve brokerages, with an average 12-month target price of $18.94. This comes after the company reported an earnings miss and weak margins in its latest quarter, though major shareholder Broadwood Partners recently increased its position. The stock's price performance reflects these challenges, trading significantly below its 200-day simple moving average.
STAAR Surgical (STAA) Posts US$80.4 Million Annual Loss Testing Turnaround Narratives
STAAR Surgical (STAA) concluded FY 2025 with an US$80.4 million annual loss, despite quarterly revenue fluctuations. The company's revenue growth of 12.1% outpaced the US market benchmark, leading to a "bull case" scenario that projects profitability within three years. However, critics point to consistently expanding losses over five years and volatile quarterly earnings, questioning whether the turnaround is truly underway or if the current valuation premium is justified.
STAAR Surgical Company (NASDAQ:STAA) Q4 2025 Earnings Call Transcript
STAAR Surgical Company (NASDAQ:STAA) reported its Q4 2025 earnings, with interim co-CEOs Warren Foust and Deborah Andrews outlining a strategy focused on growth, profitability, and innovation for 2026 after a challenging 2025. The company saw net sales of $57.8 million, an improvement in adjusted EBITDA, and emphasized efforts to stabilize the China market, reduce operating costs, and expand product offerings like EVO+ and the Lioli injector. Despite not providing 2026 guidance, STAAR anticipates significant sales increases and a return to profitability, driven by disciplined cost management, expanding market reach, and new product introductions.
Vanguard Group Inc. Has $114.71 Million Stock Holdings in STAAR Surgical Company $STAA
Vanguard Group Inc. recently reduced its stake in STAAR Surgical Company by 2.8% but still holds 4,269,123 shares valued at $114.71 million, representing about 8.65% of the company. Institutional investors collectively own approximately 96.7% of the stock. Despite a Q4 earnings miss and a consensus "Reduce" rating from analysts, management is targeting a return to profitability in 2026, supported by strong China sales and margin improvements.
STAA: Wells Fargo Lowers Price Target by 47.97% on Staar Surgica
Wells Fargo has significantly lowered its price target for Staar Surgical (STAA) to $16.00, representing a 47.97% decrease from its previous target, while maintaining an "Equal-Weight" rating. This adjustment by analyst Simran Kaur reflects a challenging market environment for the medical device company. Other analysts have also recently adjusted their ratings and price targets for STAA, contributing to an average target price of $19.72 among 9 analysts, implying a 6.66% upside from its current price.
Wells Fargo & Company Cuts STAAR Surgical (NASDAQ:STAA) Price Target to $16.00
Wells Fargo & Company has lowered its price target for STAAR Surgical (NASDAQ:STAA) from $30.75 to $16.00, maintaining an "equal weight" rating, due to the company's disappointing Q4 earnings. STAAR Surgical reported a loss of ($0.37) per share and revenue of $57.8 million, significantly missing analyst expectations. Despite an 18.0% increase in revenue year-over-year, widening losses prompted the price target reduction, with the company aiming for profitability in 2026.
STAAR Surgical (STAA) Posts US$80.4 Million Annual Loss Testing Turnaround Narratives
STAAR Surgical (STAA) reported an annual loss of US$80.4 million for FY 2025, with Q4 revenue at US$57.8 million and a basic EPS loss of US$0.37. While the company's 12.1% revenue growth outpaced the US market benchmark, critics point to expanding losses over five years and volatile quarterly earnings, questioning the turnaround narrative. However, bulls highlight strong revenue growth, forecast 91.38% earnings growth, and a DCF fair value significantly above the current share price as signs of future recovery and operating leverage.
STAAR Surgical (NASDAQ:STAA) Shares Gap Down Following Weak Earnings
STAAR Surgical (NASDAQ:STAA) experienced a significant premarket gap down after reporting weaker-than-expected Q4 earnings, missing consensus estimates for both EPS and revenue. Despite an 18% year-over-year revenue growth driven by strong China sales and increased adoption of EVO ICL, the company posted a negative EPS of -$0.37 against a $0.14 consensus and revenue of $57.8M versus an anticipated $75.5M. Analysts have reacted by cutting price targets due to near-term demand headwinds, though some investor confidence is present through recent insider and institutional buying.
Eye implant maker targets China rebound and older patients in 2026
STAAR Surgical (NASDAQ: STAA) has outlined its plans for renewed growth and profitability in 2026, focusing on a rebound in the China market, where conditions stabilized in 2025 and demand for its EVO+ ICL is strong. The company also aims to expand its market by targeting older patients in the U.S. following FDA approval and maintaining cost discipline to improve operating margins. These strategies are detailed in a shareholder letter issued by its interim co-CEOs, emphasizing innovation and strategic execution after a challenging 2025.
STAAR Surgical (NASDAQ:STAA) Misses Q4 CY2025 Sales Expectations, Stock Drops 11.2%
STAAR Surgical (NASDAQ:STAA) reported Q4 CY2025 revenue of $57.8 million, missing analyst estimates of $75.81 million, despite an 18.1% year-on-year sales increase. The company also posted a GAAP loss of $0.37 per share, significantly below consensus, leading to an 11.2% drop in its stock price. Despite the misses, management expressed optimism for sustained profitability and growth in fiscal year 2026, driven by ongoing rebalancing of distributor inventory and disciplined expense management.
Staar Surgical co-CEOs address shareholders, poor Q4 earnings
Staar Surgical's co-CEOs, Warren Foust and Deborah Andrews, released a letter to shareholders addressing the company's poor Q4 earnings, which showed a net loss of $18.3 million and missed Wall Street's revenue predictions. They attributed the difficult 2025 to macroeconomic headwinds, particularly in China, and the uncertainty surrounding the failed merger with Alcon. Despite the challenges, the co-CEOs expressed confidence in a better 2026, anticipating growth, improved profitability, and progress in their innovation pipeline, driven by cost discipline and the launch of EVO+ ICL in China.
STAAR Surgical (NASDAQ:STAA) Misses Q4 CY2025 Sales Expectations, Stock Drops 11.2%
STAAR Surgical (NASDAQ:STAA) missed Wall Street's revenue and EPS expectations for Q4 CY2025, with revenue of $57.8 million falling short of estimates and GAAP loss per share at -$0.37. Despite an 18.1% year-on-year revenue increase, the company's stock dropped 11.2% immediately after the report due to significant misses in sales, EPS, and Adjusted EBITDA. Analysts, however, project substantial revenue growth and a positive flip in EPS for STAAR Surgical over the next 12 months.
